Skip to content

Geriatric Core Dataset (G-CODE) for Clinical Research in Elderly Cancer Patients

Multidisciplinary Development of the Geriatric Core Dataset for Clinical Research in Older Patients With Cancer: A French Initiative With International Survey

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03976531
Acronym
G-CODE
Enrollment
42
Registered
2019-06-06
Start date
2015-01-01
Completion date
2017-01-01
Last updated
2021-01-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Keywords

cancer, elderly, randomized trial, consensus

Brief summary

Older adults with cancer remain underrepresented in cancer clinical trials that establish new standards of care. Geriatric assessment (GA) is defined by geriatricians as a multidimensional interdisciplinary assessment of the general health stat us of the older patient, reviewing the medical, psychosocial, functional and environmental domains. For each domain, several tools are available, but consensus is lacking on which tool to use and the optimal cut-offs or threshold scores. The literature supports the prognostic value of the GA and its utility in weighing the benefits and risks of cancer treatments in older adults. However, GA has not been implemented in routine oncology practice or in cancer clinical trials. The objective of this project is to develop a set of geriatric data, the Geriatric Core Dataset (G-CODE), to be collected in cancer trials of older patients. The methods rely on a consensus process involving international experts in the field of oncology and geriatrics.

Detailed description

Although cancer is prevalent in the older segment of the population, older adults with cancer remain underrepresented in cancer clinical trials that establish new standards of care. As a result, robust data on the benefit/risk balance are lacking for many treatment strategies in these patients. Ageing is a heterogeneous process that stresses the clinical need to identify comorbid conditions and ageing-related physiologic changes, both well-known factors increasing the risk of treatment side-effects and poor outcomes. Geriatric assessment (GA) is defined by geriatricians as a multidimensional interdisciplinary assessment of the general health stat us of the older patient, reviewing the medical, psychosocial, functional and environmental domains. For each domain, several tools are available, but consensus is lacking on which tool to use and the optimal cut-offs or threshold scores. The literature supports the prognostic value of the GA and its utility in weighing the benefits and risks of cancer treatments in older adults. However, GA has not been implemented in routine oncology practice or in cancer clinical trials. In 2011, after a workshop on clinical trial methodology in older adults with cancer, the Elderly Task Force of the European Organization for Research and Treatment of Cancer (EORTC) recommended the use of a standardised minimum data set (minDS) for assessing the global health and functional status of older populations. This minDS consisted of the G8 screening tool, the Instrumental Activities of Daily Living Following a consensus approach, a panel of 14 geriatricians from oncology clinics identified seven domains of importance in geriatric assessment. Based on the international recommendations, geriatricians selected the mostly commonly used tools/items for geriatric assessment by domain. The Geriatric Core Dataset (G-CODE) was progressively developed according to RAND appropriateness ratings and feedback during three successive Delphi rounds. The face validity of the G-CODE was assessed with two large panels of health professionals (55 national and 42 international experts) involved both in clinical practice and cancer trials.

Interventions

None listed

Sponsors

Plate-forme PACAN (Elderly and Cancer Platform)
CollaboratorOTHER
European Georges Pompidou Hospital
CollaboratorOTHER
Hospital Ambroise Paré Paris
CollaboratorOTHER
Institut Curie
CollaboratorOTHER
Centre Leon Berard
CollaboratorOTHER
Institut Claudius Regaud
CollaboratorOTHER
Saint-Louis Hospital, Paris, France
CollaboratorOTHER
Hospital Avicenne
CollaboratorOTHER
Göteborg University
CollaboratorOTHER
Oslo University Hospital
CollaboratorOTHER
City of Hope Comprehensive Cancer Center
CollaboratorOTHER
Institut Bergonié
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* cancer specialists (medical oncologists, surgeons, radiation oncologists, geriatricians, disease-oriented oncologists, clinical oncologists) * clinical research associates * nurses.

Design outcomes

Primary

MeasureTime frame
Number of Experts Who Considered That the Question Do You Live Alone ? Should be Retained in the G-CODEDay 1
Number of Experts Who Considered That the Question do You Have a Person or Caregiver Able to Provide Care and Support Should be Retained in the G-CODEDay 1
Number of Experts Who Considered That the Tool ADL (Activities of Daily Living) Should be Retained in the G-CODEDay 1
Number of Experts Who Considered That the Tool 4-IADL (Instrumental Activities of Daily Living) Should be Retained in the G-CODEDay 1
Number of Experts Who Considered That the Test Timed Up and Go Should be Retained in the G-CODEDay 1
Number of Experts Who Considered That the Items Weight Loss During the Past 6 Months and Body Mass Index (BMI) Should be Retained in the G-CODEDay 1
Number of Experts Who Considered That the Item One Cognitive Scale (Mini-Cog) Should be Retained in the G-CODEDay 1
Number of Experts Who Considered That the Item Char Lson Comorbidity Index Should be Retained in the G-CODEDay 1

Countries

France

Participant flow

Participants by arm

ArmCount
National Panel of Experts
National panel of experts involved in the scoring of the items/tools to be included in the G-CODE.
42
Total42

Baseline characteristics

CharacteristicNational Panel of Experts
Age, Customized
>= 18 years
42 Participants
Sex: Female, Male
Female
16 Participants
Sex: Female, Male
Male
26 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 42
other
Total, other adverse events
0 / 42
serious
Total, serious adverse events
0 / 42

Outcome results

Primary

Number of Experts Who Considered That the Item Char Lson Comorbidity Index Should be Retained in the G-CODE

Time frame: Day 1

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
National Panel of ExpertsNumber of Experts Who Considered That the Item Char Lson Comorbidity Index Should be Retained in the G-CODE42 Participants
Primary

Number of Experts Who Considered That the Item One Cognitive Scale (Mini-Cog) Should be Retained in the G-CODE

Time frame: Day 1

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
National Panel of ExpertsNumber of Experts Who Considered That the Item One Cognitive Scale (Mini-Cog) Should be Retained in the G-CODE42 Participants
Primary

Number of Experts Who Considered That the Items Weight Loss During the Past 6 Months and Body Mass Index (BMI) Should be Retained in the G-CODE

Time frame: Day 1

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
National Panel of ExpertsNumber of Experts Who Considered That the Items Weight Loss During the Past 6 Months and Body Mass Index (BMI) Should be Retained in the G-CODE42 Participants
Primary

Number of Experts Who Considered That the Question do You Have a Person or Caregiver Able to Provide Care and Support Should be Retained in the G-CODE

Time frame: Day 1

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
National Panel of ExpertsNumber of Experts Who Considered That the Question do You Have a Person or Caregiver Able to Provide Care and Support Should be Retained in the G-CODE42 Participants
Primary

Number of Experts Who Considered That the Question Do You Live Alone ? Should be Retained in the G-CODE

Time frame: Day 1

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
National Panel of ExpertsNumber of Experts Who Considered That the Question Do You Live Alone ? Should be Retained in the G-CODE42 Participants
Primary

Number of Experts Who Considered That the Test Timed Up and Go Should be Retained in the G-CODE

Time frame: Day 1

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
National Panel of ExpertsNumber of Experts Who Considered That the Test Timed Up and Go Should be Retained in the G-CODE42 Participants
Primary

Number of Experts Who Considered That the Tool 4-IADL (Instrumental Activities of Daily Living) Should be Retained in the G-CODE

Time frame: Day 1

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
National Panel of ExpertsNumber of Experts Who Considered That the Tool 4-IADL (Instrumental Activities of Daily Living) Should be Retained in the G-CODE42 Participants
Primary

Number of Experts Who Considered That the Tool ADL (Activities of Daily Living) Should be Retained in the G-CODE

Time frame: Day 1

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
National Panel of ExpertsNumber of Experts Who Considered That the Tool ADL (Activities of Daily Living) Should be Retained in the G-CODE42 Participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026